Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherClinical Investigations

Clinical Impact of 18F-FDG PET in Thyroid Carcinoma Patients with Elevated Thyroglobulin Levels and Negative 131I Scanning Results After Therapy

Badia O. Helal, Pascal Merlet, Marie-Elisabeth Toubert, Brigitte Franc, Claire Schvartz, Halène Gauthier-Koelesnikov, Alain Prigent and André Syrota
Journal of Nuclear Medicine October 2001, 42 (10) 1464-1469;
Badia O. Helal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pascal Merlet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Elisabeth Toubert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brigitte Franc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire Schvartz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Halène Gauthier-Koelesnikov
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alain Prigent
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
André Syrota
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

18F-FDG PET has been shown to effectively detect differentiated thyroid carcinoma (DTC) metastases with impaired iodine-trapping ability. This article evaluates the potential contribution of FDG PET in the follow-up of patients with differentiated thyroid carcinoma, elevated thyroglobulin (Tg) levels, and negative whole-body scan results obtained after high doses of 131I. Methods: We prospectively assessed the ability of FDG to detect metastases in 37 DTC patients who had undergone total thyroidectomy and radioactive ablation and presented with persistent disease, as assessed from elevated Tg levels and negative results of whole-body scans performed after therapeutic doses of 131I. Additional conventional imaging procedures were performed to detect residual disease, and the patients were divided into 2 groups: group 1, with positive conventional imaging findings (n = 10), and group 2, with negative conventional imaging findings (n = 27). Results: FDG PET showed positive findings in 28 patients and accurately localized tumor sites in 89% of them. In group 1, FDG PET confirmed 17 of 18 previously known tumor sites and detected 11 additional sites. In group 2, FDG PET findings were positive in 19 of 27 patients with no previously detected metastases. PET was effective for both low- and high-stage tumors. The FDG data led to a change in the clinical management of 29 of 37 patients with further surgical resection in 23 patients, 14 of whom achieved disease-free status, and external radiation therapy in 4 patients. Conclusion: FDG PET is able to detect metastases undetected by 131I posttherapy whole-body scanning in patients with elevated Tg levels. It should be proposed as a first-line investigation in patients with persistent disease but negative findings on 131I whole-body scans after treatment.

  • FDG PET
  • differentiated thyroid carcinoma
  • 131I posttherapy scan

During the follow-up of patients with differentiated thyroid carcinoma (DTC) treated by total thyroidectomy and radioactive iodine (RAI) ablation therapy, an elevated serum thyroglobulin (Tg) concentration is a sensitive marker indicating persistent or recurrent disease (1). Elevated serum Tg concentration is usually associated with positive 131I whole-body scan findings (2,3). However, some patients have true metastases that do not concentrate 131I, even when it is given in therapeutic doses (4). Metastases unable to concentrate 131I are often associated with aggressive clinical behavior (5,6) and must be thoroughly assessed. Morphologic imaging procedures, which include sonography, CT, MRI, or nuclear imaging procedures to detect and localize lesions, can be used to propose the most appropriate therapeutic options. The use of 18F-FDG for PET has recently been established as an important new noniodine radionuclide imaging tool in clinical oncology (7). Several studies have shown that, in differentiated thyroid carcinoma, FDG PET can be used to detect recurrence or metastases with a high degree of sensitivity (80%–90%), which is especially valuable for those that do not take up RAI (8–12). The purpose of this study was to assess the clinical impact of FDG PET on the management of the few patients with differentiated thyroid carcinoma who had elevated Tg levels and negative 131I whole-body scan results obtained after therapeutic doses of 131I.

Materials and Methods

Patients

Thirty-seven patients (19 men, 18 women; age range, 27–78 y; mean age, 50.2 y) with pathologically proven DTC, negative 131I whole-body scan results after treatment, and elevated Tg levels were prospectively and consecutively submitted to FDG PET evaluation at our hospital. The initial treatment of the thyroid carcinomas, which consisted of total thyroidectomy followed by 131I therapy (3.7 GBq) for the ablation of thyroid remnants, had been performed at various hospitals. Thirty of the 37 patients had undergone lymph-node dissection. During follow-up, the patients had received 1–6 therapeutic doses of 131I to treat persistent or recurrent disease, with an average cumulative dose of 10.2 GBq 131I and with a maximum cumulative dose of 22.2 GBq. Five patients had also required 3 successive cervical lymph node dissections and another 2 were submitted to external neck radiotherapy. The pathologic findings consisted of papillary thyroid carcinoma in 26 patients and follicular thyroid carcinoma in 11 patients, including 4 Hürthle-cell carcinomas. The clinical and pathologic staging was performed according to the American Joint Committee on Cancer and represents the highest stage reached during follow-up before FDG PET evaluation. The pathologic tumor stages were as follows: T1 in 2 patients, T2 in 5 patients, T3 in 12 patients, and T4 in 18 patients; the clinical stages were as follows: 15 stage I, 2 stage II, 16 stage III, and 4 stage IV patients (13). All patients gave written informed consent to participate in the study as required by the hospital’s ethics committee and those with diabetes mellitus were not included.

131I Whole-Body Scan After Therapy

Because of an increase in Tg levels during thyroid-stimulating hormone (TSH) suppression, a therapeutic dose of 131I was given to each patient 4 wk after l-thyroxine withdrawal (it was the second dose for 1 patient, the third for 20, the fourth for 9, the fifth for 6, and the sixth for 1 patient). Consequently, whole-body scanning was performed 4–5 d after the therapeutic dose of 3.7 GBq 131I, using a dual-head large-field gamma camera equipped with a high-energy collimator. Whole-body scan results were negative in all patients: no clear focus of abnormal iodine uptake was observed by visual inspection after checking for the absence of iodine contamination.

Tg and Antithyroglobulin Antibody Measurement

Blood samples for measuring serum Tg and anti-Tg antibody were taken during l-thyroxine withdrawal at the time of the whole-body scan and during suppression therapy. Using a commercial kit (BioRad Tg, Pasteur, France; and Dynotest antiTgn, Brahms, France) Tg and anti-Tg levels were determined by radioimmunoassay. Serum Tg levels were classified as abnormal if values >1 μg/L were found during TSH suppression or >10 μg/L were found during TSH stimulation. Tg antibody test results were negative in all patients.

Conventional Imaging

Additional conventional imaging (CI) procedures, including chest x-rays (all patients), neck sonography (all patients), thoracic CT (n = 28), MRI (n = 6), and bone scintigraphy (n = 8) performed after the negative whole-body scan results were obtained. To assess the role of FDG PET as an imaging strategy for patients with negative 131I posttherapy scan results, the patients were divided in 2 groups: group 1, which consisted of 10 patients with positive CI results, and group 2, which consisted of 27 patients with negative CI findings.

FDG PET Imaging

All patients underwent FDG PET imaging during thyroxine therapy <3 mo after the negative posttherapy whole-body scan. The PET scan was performed 50–60 min after injection of 370 MBq FDG (after a fasting period of 12 h). PET data were obtained using an ECAT EXACT HR+ high-resolution whole-body scanner (Siemens-CTI, Knoxville, TN) with an axial field of view of 15.5 cm. All scanning was performed in 3-dimensional mode. The average axial resolution varied between 4.1-mm full width at half maximum in the center and 7.8 mm at 20 cm. Emission scanning was performed from the head to the femur for 7 min at each bed position. Images were reconstructed using filtered backprojection with a Hanning filter and a cutoff frequency of 0.4. No attenuation correction was applied and the total scanning time was approximately 1 h. Transaxial, sagittal, and coronal images were examined on a computer display monitor. Scans were interpreted independently by 2 experienced physicians blinded to the clinical situation and any disagreement was resolved by consensus. A visually abnormal focus of FDG uptake was defined as a focal uptake relatively higher than that of surrounding tissue with no similar activity seen in the contralateral side of the body. Lung metastases were arbitrarily classified as multiple if >4 sites were detected.

Statistical Analysis

Tumor detection rates were expressed as the percentage of patients with positive sites and compared using χ2. The threshold of significance was set at 0.05.

Results

FDG PET findings were positive in 28 of the 37 patients (76%) and CI findings were positive in 10 patients (27%), as summarized in Tables 1 and 2.

View this table:
  • View inline
  • View popup
TABLE 1

Patients with Positive CI Findings

View this table:
  • View inline
  • View popup
TABLE 2

Patients with Negative CI Findings

In the 10 patients in group 1 (Table 1), FDG confirmed 17 of 18 known tumor sites and detected an additional 11 sites. PET scanning detected cervical and mediastinal lymph nodes in 5 patients and distant metastases (lung and bone) in 5 patients. FDG imaging failed to detect a cervical lymph node metastasis in 1 patient. This was removed surgically and confirmed by histopathology. Figure 1 illustrates the case of patient 5, who was known to have lung metastases from Hürthle-cell carcinoma; FDG PET identified multiple lung metastases and an unknown mediastinal lymph node metastasis.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

A 64-y-old woman with lung metastases from Hürthle-cell carcinoma. FDG PET confirmed lung metastases and revealed mediastinal lymph node metastasis. (A) Coronal slice shows both right lung and mediastinal lymph node metastases. (B) Axial slice confirms multiple left lung metastases (patient 5, group 1).

FDG results were positive in 19 of the 27 patients in group 2 and scanning identified 44 tumor sites (Table 2) affecting the following tissues: neck (n = 14 patients), mediastinum (n = 2), lung (n = 3), and bone (n = 2). FDG scanning results were negative in 8 patients. Figure 2 illustrates the case of patient 27, who had persistent papillary carcinoma disease despite total thyroidectomy, 2 therapeutic doses of 131I, and 2 cervical lymph node dissections. FDG detected 2 cervical lymph node metastases, despite negative sonography findings, that were surgically removed and pathologically confirmed.

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

A 28-y-old man with papillary thyroid cancer who had previously required 2 cervical lymph node dissections. Neck sonography was negative, but FDG visualized on the coronal (A) and sagittal (B) slices 2 right cervical lymph nodes that were confirmed pathologically to be metastases (patient 27, group 2).

Overall, 9 cases of follicular carcinoma, including the 4 Hürthle-cell carcinomas, and 15 of 26 papillary carcinomas had positive PET findings. There was no statistical difference between the 2 groups with regard to FDG results (P > 0.05). For all types of cancer, the detection rate was significantly higher for stages III and IV (80%) than for stages I and II (47%) (P < 0.05). Malignancy was confirmed in 24 patients by biopsy (4 patients) or surgery (20 patients). In 2 patients, metastatic disease was assessed by repeated sonography and CT or MRI. The PET findings led to a change in the management of 29 patients. Twenty-three patients underwent surgery for removal of a residual tumor, and the disease was pathologically confirmed in 20 of them. Fourteen of these patients achieved disease-free status with a mean follow-up interval of 6 mo (range, 3–24 mo). Four patients were treated with external radiotherapy because their lesions were not amenable to surgical excision. One patient with multiple mediastinal and lung metastases was placed on differentiation therapy in an attempt to stimulate 131I uptake, and 1 patient declined further treatment. In 3 patients, in whom PET had identified high FDG uptake in cervical lymph nodes, pathology examinations revealed inflammatory disease.

Regardless of the imaging procedures used, the 8 negative and the 3 false-positive patients with persistent elevated Tg values continued to be carefully followed up until the end of the study, and, at the time of writing, remain without detectable metastases.

Discussion

Our study of 37 DTC patients with elevated Tg levels shows that FDG PET has a high metastasis detection rate in cases undetected by 131I posttherapy whole-body scanning. FDG findings were positive in 76% of patients and accurately localized the disease in 89% of them.

After the ablation of residual thyroid tissue, measurement of serum Tg levels and 131I imaging usually provide sensitive tools for the early detection of recurrence. Unfortunately, a few patients with elevated Tg have tumors that do not take up 131I even after administration of therapeutic doses, because of an impaired ability to trap iodine. FDG PET appears to offer an accurate functional method of detecting such tumors. This method has been shown to be highly sensitive in detecting thyroid carcinoma metastases, especially in the absence of 131I uptake (10–12). However, most of the studies have involved patients with negative results obtained from scanning performed after diagnostic doses of 131I (9,10,12,14). Alnafisi et al. (15) recently reported the effectiveness of FDG in 11 patients with persistent disease and negative 131I whole-body scan results after therapy. However, their study was restricted to papillary thyroid carcinomas.

Our study shows that FDG is more effective than CI, with positive findings in 27 of 37 patients (70%) versus positive CI findings in 10 of 37 patients (27%) (P < 0.001). Morphologic imaging procedures are known to have low specificity—particularly in cases with postsurgical anatomic changes—and low sensitivity, because of their limited viewing field (16). In contrast, the PET scanner makes it possible to perform a whole-body examination with tomographic imaging, greater spatial resolution, and, therefore, high sensitivity. Furthermore, FDG PET is able to focus on a specific area of the body, thus facilitating radiologic interpretation.

Wang et al. (12) suggested that FDG uptake may correlate with the (tumor, node, and metastases [TNM]) stage of thyroid cancer. We found a significant correlation between FDG uptake and the stage of the thyroid cancer in both papillary carcinoma and follicular carcinoma. But, unlike Wang et al., we found that FDG was also effective in low-stage patients, because 5 of 6 of the patients with positive findings were confirmed to have stage-I cancer even after FDG. Only 1 patient seemed to have been understaged, because FDG evaluation revealed bone metastases and this patient was consequently classified as having stage IV cancer. It is important to note that all our patients had elevated Tg levels.

PET scanning failed to detect any tumor tissue in 9 patients with persistent disease. This may have been attributable to a need to stimulate tumor foci by TSH or to some other methodologic problem. The possible effect of thyroxine on the accumulation of FDG in thyroid metastases has not yet been established, and all our PET scanning was performed while the patients were on thyroxine therapy. Although many authors have not observed any significant correlation between FDG uptake and thyroid hormone levels (10,12), others have reported a significant increase in FDG uptake in response to TSH stimulation (17,18). Further studies using recombinant TSH may clarify the effect of TSH on FDG uptake without the disadvantage of l-thyroxine withdrawal.

Because the whole-body PET imaging in this study was performed without correction for tissue attenuation, deep tumors may have been missed because of their less obvious activity, with the possible consequence of a false-negative interpretation. However, in our group of patients we found that the only true-negative FDG result corresponded to a superficial cervical lymph node metastasis. Moreover, several clinical studies comparing images with and without attenuation correction showed no difference in tumor PET for lesion detection (19,20). In a series of 15 patients, Cutle (21) found no difference between corrected and uncorrected images with regard to the number and location of lesions found by experienced observers.

Conclusion

PET using FDG is of undeniable clinical value in patients with negative 131I posttherapy whole-body scan results who are suspected of having a metastatic thyroid disease. It is able to detect significantly more tumor sites than can CI procedures. FDG may become a guide for additional imaging procedures, making it possible to detect Tg production sites accessible to surgery or external radiation therapy. We suggest that FDG PET be used as first-line investigation in patients with negative 131I posttherapy scan results and elevated Tg levels.

Footnotes

  • Received Jan. 26, 2001; revision accepted Jun. 13, 2001.

    For correspondence or reprints contact: Badia O. Helal, MD, Service de Médecine Nucléaire, Hôpital Antoine Béclère, 157, rue de la Porte de Trivaux, 92141 Clamart CEDEX, France.

References

  1. ↵
    Spencer CA. Thyroglobulin. In: Braverman LE, Utiger RD, eds. Werner and Ingbar’s The Thyroid: Fundamental and Clinical Text 7th ed. Philadelphia, PA: Lippincott-Raven; 1996:406–415.
  2. ↵
    Filesi M, Signore A, Ventroni G, Melacrinis F, Ronga G. Role of initial iodine-131 whole body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases. J Nucl Med 1998;39:1542–1546.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Schlumberger M, Arcanglioli O, Piekarski JD, Tubiana M, Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest x-rays. J Nucl Med 1988;29:1790–1794.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab. 1995;80:1488–1492.
  5. ↵
    Schlumberger M. Papillary and follicular carcinoma. N Engl J Med 1998;338:297–306.
    OpenUrlCrossRefPubMed
  6. ↵
    Nakada K, Katoh C, Kanegae K, et al. Thallium-201 scintigraphy to predict therapeutic outcome of iodine-131 therapy of metastatic thyroid carcinoma. J Nucl Med 1998;39:807–810.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Stauss LG, Conti PS. The application of PET in clinical oncology. J Nucl Med 1991;32:623–648.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Ichiya Y, Kuwabata Y, Osuka M, et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1991;23:312–319.
    OpenUrl
  9. ↵
    Grünwald F, Schomburg A, Bender H, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996;23:312–319.
    OpenUrlCrossRefPubMed
  10. ↵
    Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, Müller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468–1472.
    OpenUrlAbstract/FREE Full Text
  11. Dietlein A, Cheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997;24:1342–1348.
    OpenUrlCrossRefPubMed
  12. ↵
    Wang W, Macapinlac H, Larson SM, et al. [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole-body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999;84:2291–2302.
    OpenUrlCrossRefPubMed
  13. ↵
    Fleming ID, Cooper JS, Henson DE, et al. Thyroid gland. In: Fleming ID, Cooper JS, Henson DE, et al., eds. American Joint Committee on Cancer: AJCC Cancer Staging Manual 5th ed. Philadelphia, PA: Lippincott-Raven; 1997:59–61.
  14. ↵
    Chung JK, So Y, Lee JS, et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 1999;40:986–992.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Alnafisi NS, Driedger AA, Cates G, Moote DJ, SJ Raphael. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. J Nucl Med 2000;41:1010–1015.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Grünwald F, Käliche T, Feine U, Lietzenmayer R. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547–1552.
    OpenUrlCrossRefPubMed
  17. ↵
    Sisson JC, Ackerman RJ, Meyer MA, Wahl RL. Uptake of 18-fluoro-2-deoxy-d-glugose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab 1993;77:1090–1094.
    OpenUrlCrossRefPubMed
  18. ↵
    Moog F, Linke R, Tiling R, et al. The influence of TSH levels on the uptake of F-18-FDG in metastatic thyroid cancer [abstract]. Eur J Nucl Med 1999;26.(suppl):1014p.
  19. ↵
    Bengel FM, Ziegler SI, Avril N, Weber W, Laubenbacher C, Shwaiger M. Whole-body positron emission tomography in clinical oncology: comparison between attenuation-corrected and uncorrected images. Eur J Nucl Med 1997;24:1091–1098.
    OpenUrlPubMed
  20. ↵
    Blecmann C, Dose J, Bohuslavizki KH, et al. Effect of attenuation correction on lesion detectability in FDG PET of breast cancer. J Nucl Med 1999;40:2021–2024.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Cutle PD. Design of an ROC study using a simulated lesions in whole-body FDG PET. Proceedings of the 1998 IEEE Nuclear Science Symposium and Medical Imaging Conference [CD-ROM]. 1998.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 42, Issue 10
October 1, 2001
  • Table of Contents
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clinical Impact of 18F-FDG PET in Thyroid Carcinoma Patients with Elevated Thyroglobulin Levels and Negative 131I Scanning Results After Therapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Clinical Impact of 18F-FDG PET in Thyroid Carcinoma Patients with Elevated Thyroglobulin Levels and Negative 131I Scanning Results After Therapy
Badia O. Helal, Pascal Merlet, Marie-Elisabeth Toubert, Brigitte Franc, Claire Schvartz, Halène Gauthier-Koelesnikov, Alain Prigent, André Syrota
Journal of Nuclear Medicine Oct 2001, 42 (10) 1464-1469;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Clinical Impact of 18F-FDG PET in Thyroid Carcinoma Patients with Elevated Thyroglobulin Levels and Negative 131I Scanning Results After Therapy
Badia O. Helal, Pascal Merlet, Marie-Elisabeth Toubert, Brigitte Franc, Claire Schvartz, Halène Gauthier-Koelesnikov, Alain Prigent, André Syrota
Journal of Nuclear Medicine Oct 2001, 42 (10) 1464-1469;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • The role of F-18-fluorodeoxyglucose positron emission tomography in the postoperative evaluation of differentiated thyroid cancer
  • Comparison of 18F-FDG PET and Bone Scintigraphy in Detection of Bone Metastases of Thyroid Cancer
  • 18F-FDG PET/CT in Patients with Suspected Recurrent or Metastatic Well-Differentiated Thyroid Cancer
  • European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.
  • Empirically Treating High Serum Thyroglobulin Levels
  • PET in the follow-up of differentiated thyroid cancer
  • Clinical Impact of 18F-FDG PET in Thyroid Carcinoma Patients with Elevated Thyroglobulin Levels and Negative 131I Scanning Results After Therapy
  • Google Scholar

More in this TOC Section

  • Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure
  • Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System
  • Prognostic Role of 68Ga-PSMA11 PET–Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy
Show more Clinical Investigations

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire